Ignite Creation Date:
2025-12-25 @ 4:32 AM
Ignite Modification Date:
2026-03-12 @ 9:29 AM
Study NCT ID:
NCT01345318
Status:
COMPLETED
Last Update Posted:
2024-01-12
First Post:
2011-04-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
B0151005 Open-Label Extension Study
Sponsor:
Pfizer
Organization:
Study Overview
Official Title:
A Multicenter Open-label Extension Study For Subjects Who Participated In Study B0151003 (Andante Ii)
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANDANTE II
Brief Summary:
This is a multi-center Phase 2, open label, safety extension study in subjects with moderate to severe CD who are anti-TNF inadequate responders. Subjects eligible for this study will have completed the 12-week induction period of study B0151003 and will be enrolled as either responders or non responders.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: